Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient

Launched by UNIVERSITAS PADJADJARAN · Sep 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a treatment called purified protein derivative (PPD) for patients with anogenital warts, especially those living with HIV. Anogenital warts are caused by a virus and are more common in people with HIV, who face a higher risk of developing these warts. The trial aims to see how well PPD helps reduce the size of these warts and improve the immune response in patients with and without HIV.

To participate in the trial, individuals must be diagnosed with anogenital warts based on a medical examination and must not have certain allergies or conditions that could interfere with their response to the treatment. Participants will receive injections of PPD, and their progress will be monitored over time. This trial is important because it seeks to understand how PPD therapy works differently in HIV-infected patients compared to those who are not, potentially leading to better treatment options for all individuals with anogenital warts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Anogenital warts whose diagnosis is made based on anamnesis and physical examination, before receiving intralesional purified protein derivative injection therapy.
• • 2. All stored biological materials that have been previously taken through tissue from anogenital warts patients whose diagnosis was confirmed based on history and physical examination, 3 weeks after receiving the first intralesional purified protein derivative injection therapy.
• Exclusion Criteria:
• • 1. With a history of allergies to purified protein derivative, generalized dermatitis, asthma and skin allergies 2. Currently taking immunosuppressant or immunomodulatory drugs based on the history and clinical examination.
• • 3. Have an immunodeficiency disease based on anamnesis and clinical examination, except for HIV based on anamnesis, clinical examination and serological examination (anti-HIV).
• • 4. Have a history of suffering from malignancy based on history and clinical examination.
• • 5. Infected with tuberculosis based on history, clinical examination and chest radiography.
• • 6. Infected with other STIs based on history, clinical examination, and serological examination (venereal disease research laboratory (VDRL), Treponema pallidum hemagglutination assay (TPHA), and Hepatitis B surface antigen (HBsAg)).